On June 7, 2018 Atreca, Inc., a biotechnology company focused on developing novel therapeutics based on a deep
understanding of the human immune response, reported that Norman Michael Greenberg, Ph.D., Senior Vice President and Chief Scientific Officer at Atreca, will deliver a presentation highlighting progress of the Company’s advancing immuno- oncology pipeline during the 2018 World Preclinical Congress (WPC) Annual Meeting, which is taking place at Westin Copley Place in Boston, MA, June 18-21, 2018 (Press release, Atreca, JUN 7, 2018, View Source [SID1234527228]). Dr. Greenberg will report on results of Atreca’s R&D engine, Immune Repertoire Capture (IRC), to identify therapeutic antibodies for development based on patients’ responses to cancer immunotherapy.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The power of our IRC technology lies in its ability to accurately discover anti-ˇtumorantibodies in patients who have achieved successful outcomes following anti-cancer treatments, such as checkpoint inhibitor immunotherapy," said John A. Orwin, Atreca’s President and Chief Executive Officer. "As highlighted in this promising research, our
recombinantly expressed antibodies were able to cause tumor regression and induce durable immunity in in vivo preclinical cancer models. We are delighted to report on the progress of this and other key research at Atreca as we continue to advance our pipeline toward entry into the clinic next year."

Details regarding the oral presentation are available on the WPC website and are also
as follows:

Presentation Title: Discovery and Characterization of Functional Anti-ˇTumor Antibodies from Non-ˇProgressing Cancer Patients Undergoing Immunotherapy

Session Title: New Targets and Approaches;; Preclinical Strategies, Models & Tools in Oncology: Executive Summit
Presentation Date & Time: Tuesday, June 19, 2018, 11:05 AM ET
Location: Essex South Room, Westin Copley Place

On June 6, 2018 CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) reported that management will present at the Jefferies 2018 Global Healthcare Conference in New York, NY on Friday, June 8, 2018 at 10:30 AM ET and host one-on-one meetings (Press release, CTI BioPharma, JUN 6, 2018, View Source;p=RssLanding&cat=news&id=2353463 [SID1234527196]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be webcast live and available for replay from the Investors section of CTI BioPharma’s website at www.ctibiopharma.com.

On June 6, 2018 Seattle Genetics, Inc. (NASDAQ:SGEN) reported that management will present at the Goldman Sachs 39th Annual Global Healthcare Conference on Wednesday, June 13, 2018 at 1:20 p.m. Pacific Time (Press release, Seattle Genetics, JUN 6, 2018, View Source;p=RssLanding&cat=news&id=2353475 [SID1234527197]). The presentation will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com in the Investors section.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On June 6, 2018 Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, reported CEO, Carsten Thiel, Ph.D., will present at the at the Jefferies 2018 Global Healthcare Conference in New York City, NY (Press release, Abeona Therapeutics, JUN 6, 2018, View Source;p=RssLanding&cat=news&id=2353504 [SID1234527199]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Event: Jefferies 2018 Global Healthcare Conference
Date: Thursday, June 7th
Presenter: Carsten Thiel, Ph.D., CEO
Presentation Time: 11:00 AM – 11:25 AM ET
Room Name: Ballroom I
Location: New York City, NY
Webcast: View Source

Abeona Recent Highlights
May 31st: Opening of Commercial Gene & Cell Therapy GMP Manufacturing Facility in Cleveland, Ohio
— The Elisa Linton Center for Rare Disease Therapies to support development of advanced gene and cell therapies for treatment of serious rare diseases.
— The GMP facility will have the capability to manufacture clinical and commercial grade products over Abeona’s multiple programs, including recessive dystrophic epidermolysis bullosa (RDEB) and Sanfilippo syndrome.

May 18th: Clinical Update on MPS IIIA Gene Therapy Trial at the 21st Annual ASGCT (Free ASGCT Whitepaper) Meeting
— Ongoing ABO-102 (AAV-SGSH) trial results demonstrate robust and durable clinical effects achieved throughout various timepoints post-administration.
— 18-month efficacy and safety data continue to demonstrate time- and dose-dependent reductions in underlying disease pathology, including decreased CSF and urine GAGs and improved liver volumes.
— 11 subjects enrolled through > 4,200 days cumulative follow up.

May 17th: Clinical Update from RDEB Gene & Cell Therapy Trial at the 21st Annual ASGCT (Free ASGCT Whitepaper) Meeting
— EB-101, the Company’s gene-corrected skin graft cell therapy for patients suffering from RDEB is safe and well-tolerated, with durable efficacy.
— Trial results demonstrate robust and durable clinical effects achieved throughout various timepoints post-administration.
— Completed Phase 1/2 clinical trial included seven patients with 42 gene-corrected EB-101 grafts, with the first patient treated over three years ago with lasting effects and closed wounds to date

On June 6, 2018 Alkermes plc (Nasdaq: ALKS) recorded that its Chief Executive Officer, Richard Pops, will participate in a fireside chat at the Goldman Sachs 39th Annual Global Healthcare Conference on Wednesday, June 13, 2018 at 3:20 p.m. PT (6:20 p.m. ET/11:20 p.m. BST) from Rancho Palos Verdes, Calif (Press release, Alkermes, JUN 6, 2018, View Source;p=RssLanding&cat=news&id=2353578 [SID1234527200]). The audio portion of the fireside chat may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases. The company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes’ website at www.alkermes.com.

Contact:
Jennifer Zibuda
Investor Relations
+1 781 609 6129